V-Go®

About Zealand Pharma

Zealand Pharma leverages its proprietary peptide platform to design and develop novel therapeutics, with a core focus on metabolic and gastrointestinal disorders. The company has achieved significant milestones, including the commercialization of V-Go® for diabetes and the advancement of a high-potential pipeline led by survodutide, a GLP-1/glucagon dual agonist with blockbuster potential in obesity. Strategic partnerships with Boehringer Ingelheim and a strong financial position underpin its strategy to become a leader in peptide therapeutics.

Therapeutic Areas